Paul Gazzara, MD
Addiction Medicine · Staten Island, NYNPI 1366417677
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $638 and has fallen 63.8% since, to $231 in 2025.
Across 137 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$530
- GSK$212
- AstraZeneca$206
- Lilly USA, LLC$176
- Edwards Lifesciences$154
- Indivior Inc.$146
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,596100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 30 | $530 |
| GSK | 10 | $212 |
| AstraZeneca | 10 | $206 |
| Lilly USA, LLC | 10 | $176 |
| Edwards Lifesciences | 2 | $154 |
| Indivior Inc. | 9 | $146 |
| Eisai Inc. | 8 | $141 |
| Pfizer | 9 | $135 |
| Novo Nordisk | 8 | $126 |
| Procept Biorobotics Corporation | 1 | $87 |
| Merck | 6 | $83 |
| Esperion Therapeutics, Inc. | 5 | $82 |
| Alkermes, Inc. | 4 | $71 |
| Astellas Pharma US Inc | 3 | $60 |
| Johnson & Johnson | 3 | $58 |
| AbbVie(2 entities) | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $30 |
| Sanofi Pasteur Inc. | 2 | $30 |
| Agios Pharmaceuticals, Inc. | 1 | $30 |
| Philips North America LLC | 2 | $29 |
| Exact Sciences | 1 | $25 |
| Bayer | 1 | $25 |
| Boehringer Ingelheim | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Circassia Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,596 in reported general payments places this provider in the 80th percentile of 125 addiction medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 71 | $70,099 |
| MounjaroTirzepatide | 46 | $47,592 |
| FarxigaDapagliflozin Propanediol | 48 | $46,595 |
| OzempicSemaglutide | 47 | $44,837 |
| TrulicityDulaglutide | 39 | $41,575 |
| ProliaDenosumab | 20 | $33,377 |
| Repatha SureclickEvolocumab | 34 | $32,652 |
| EliquisApixaban | 16 | $20,043 |
| TradjentaLinagliptin | 25 | $18,772 |
| XareltoRivaroxaban | 20 | $18,108 |
| JardianceEmpagliflozin | 13 | $11,149 |
| NexletolBempedoic Acid | 14 | $10,680 |
| LinzessLinaclotide | 13 | $7,961 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $7,227 |
| Praluent PenAlirocumab | 14 | $6,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $176 | $89,16785 claims |
| MerckJanuvia | $83 | $70,09971 claims |
| AstraZenecaFarxiga | $206 | $46,59548 claims |
| Novo NordiskOzempic | $126 | $44,83747 claims |
| AmgenProlia | $530 | $33,37720 claims |
| Boehringer IngelheimTradjenta, Jardiance | $20 | $29,92138 claims |
| PfizerEliquis, Paxlovid | $135 | $21,41127 claims |
| Johnson & JohnsonXarelto | $58 | $18,10820 claims |
| Esperion Therapeutics, Inc.Nexletol | $82 | $10,68014 claims |
| AbbVieLinzess, Synthroid | $44 | $9,33540 claims |
| GSKAnoro Ellipta | $212 | $7,22717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 125 addiction medicine providers in New York.
Other addiction medicine in Staten Island
- Jeffry TamborStaten Island$4K
- Sarup NarianiStaten Island$693
- Edmond HakimiCalverton$125K
- Alain LitwinBronx$124K
- John MarianiNew York$38K
- Stefan KantrowitzNew York$33K
- Alejo ParelladaBrooklyn$22K
- Sean ChappinAlbany$20K
- Mohammad KabirTroy$15K
- Sonia LopezJamaica$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.